摘要
目的:探讨曲妥珠单抗(HER)与顺铂(DDP)联合抑制作用最佳序贯方式以及HER对于DDP作用的影响及机制。方法:利用MTT法及流式细胞技术测定HER、DDP以及不同序贯联合应用对人乳腺癌细胞(MDA-MB453)的抑制率及细胞周期的影响。结果:两药联合应用对乳腺癌细胞的抑制效果均好于单药顺铂组(P<0.01);其中以同时使用时效果最好。使用DDP前应用HER组G0/G1、S期细胞所占比例减少,G2/M期细胞增多。结论 :曲妥珠单抗与顺铂同时应用时,可最大程度增强顺铂的抑制作用。序贯应用的差异与细胞周期的变化有关。
Objective： To investigate the best sequence of combination treatment of trastuzumab（HER） with cisplatin（DDP） on the breast cancer in vitro and its mechanism.Methods： The inhibition ratio of HER treatment,DDP treatment and HER＋DDP combination treatment in different sequences to breast cancer cells were measured by MTT and change of cell cycle was detected by flow cytometry（FCM）.Results： The inhibition ratio was better in combination treatment of HER with DDP than in the monotherapy of DDP（P 0.01）,and the simultaneous treatment was the best choice.Compared with the group of single chemotherapy,the group using HER before DDP had a better result in the decreasing of proportions of G0/G1,S phase and the increase of G2/M phase.Conclusion： Simultaneous use of HER and DDP in combination treatment had a more significant inhibition activity to breast cancer cells than other methods.The application of difference sequence in groups were related with the variance of cell cycle.
出处
《中国药物应用与监测》
CAS
2012年第1期26-28,共3页
Chinese Journal of Drug Application and Monitoring
